Company Filing History:
1 out of 98 
1 out of 40 
1 out of 12 Years Active: 1991-1994
Title: Kenneth J Natalie, Jr: Innovator in Sigma Binding Site Agents
Introduction: Kenneth J Natalie, Jr., an accomplished inventor located in Baltimore, MD, has made significant contributions to the field of pharmaceutical sciences. With a total of three patents to his name, he has focused his research and innovation on sigma binding site agents, which have important therapeutic implications.
Latest Patents: Kenneth’s latest patents include novel intermediates for making sigma binding site agents. These agents possess unique formulas that include the variable elements A1, A2, A3, B, y, and 2, as described in the specifications. Additionally, these agents are designed to inhibit activity induced by sigma binding sites in mammals. This innovation represents a step forward in the development of pharmaceutical compositions and methods aimed at addressing various health issues.
Career Highlights: Throughout his career, Kenneth has been associated with prominent companies in the pharmaceutical industry, including Guilford Pharmaceuticals, Inc. and Scios Nova, Inc. His work has not only advanced the science of sigma binding agents but has also contributed to the overall understanding of drug development and application.
Collaborations: Kenneth has collaborated with noted colleagues such as Waclaw J Rzeszotarski and Ronald H Erickson. Their teamwork exemplifies the spirit of innovation and collaboration that is essential in the research and development of pharmaceutical agents.
Conclusion: Kenneth J Natalie, Jr. stands out as a notable inventor whose work in sigma binding site agents has profound implications for medical science. His patents and collaborative efforts continue to pave the way for advancements in therapeutic solutions, showcasing the impact that dedicated inventors can have on health care and innovation.